Progenics Signs Exclusive License Agreement with Curium for the Development of PyL in EU

 Progenics Signs Exclusive License Agreement with Curium for the Development of PyL in EU

Progenics Signs Exclusive License Agreement with Curium for the Development of PyL in EU

Shots:
  • Curium to get exclusive license to develop and commercialize PyL in EU and Progenics to get royalties on the net sales
  •  The focus of the agreement is to advance the P-III CONDOR study and further commercialize it in the US
  •  PyL is PSMA -targeted Positron Emission Topography (PET) used for visualizing bone & soft tissue metastases for determining metastatic prostate cancer. In Q1’ 19 Curium to get regulatory approval for PyL

Click here to read full press release/ article | Ref: Progenics | Image: Annualreports

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post